Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
25 mai 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Closing of Public Offering of Common Stock
14 déc. 2020 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Pricing of Public Offering of Common Stock
10 déc. 2020 09h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Proposed Public Offering of Common Stock
09 déc. 2020 16h45 HE
|
Avid Bioservices, Inc
TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
07 déc. 2020 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments
02 déc. 2020 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $21.1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million -- -- Initiated First Phase of Myford Expansion --...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
01 déc. 2020 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2021 After Market Close on December 2, 2020
24 nov. 2020 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference
10 sept. 2020 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments
01 sept. 2020 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $25.4 Million -- -- Signed Three New Customers and Project Expansion Orders with Current Customers for $20 Million -- -- Backlog of $60 Million at Quarter-End --...